A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea])

Expert Opinion on Investigational Drugs

Volumn 21, Issue 3, 2012, Pages 265-279

  D'Cruz, Osmond J ^a   Qazi, Sanjive ^a   Yiv, Seang ^a   Uckun, Fatih M ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AIDS; Human immunodeficiency virus type 1; Microbicide; Non nucleoside reverse transcriptase inhibitor; Reverse transcriptase

Indexed keywords

(N-[2-(2-THIOPHENE)ETHYL]-N-[2-(5-BROMOPYRIDYL)] THIOUREA]); ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DELAVIRDINE; EFAVIRENZ; HI 443; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MICROBICIDE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; EPITHELIUM CELL; EX VIVO STUDY; FERTILITY; GENITAL SYSTEM; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; LIVER TOXICITY; LYMPHOCYTOPENIA; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; RABBIT; REVIEW; RODENT; SWINE; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL; UTERINE CERVIX MUCUS; VAGINA FLORA; VIRUS TRANSMISSION;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-HIV AGENTS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MICE; PYRIDINES; RABBITS; REVERSE TRANSCRIPTASE INHIBITORS; SWINE; THIOUREA;

EID: 84856890234     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.655422     Document Type: Review

References (85)

1. Global report 2010. Geneva: UNAIDS, 2010. Available from: http://www.unaids. org/globalreport/documents/20101123-GlobalReport-full-en.pdf
2. Virginia Department of Health. The impact of HIV/AIDS among black women in Virginia. VDH: Division of Disease Prevention (HIV, STD, TB RX) August 2006
3. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008;8:447-57. (Pubitemid 351735878)
4. Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009;6:20-8.
5. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010;464:217-23
6. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011;62:127-39.
7. Uckun FM, D'Cruz OJ. Prophylactic contraceptives for HIV/AIDS. Hum Reprod Update 1999;5:506-14 (Pubitemid 29512137)
8. D'Cruz OJ, Uckun FM. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 2006;57:411-23 (Pubitemid 43240192)
9. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008;59:455-71 (Pubitemid 351287949)
10. D'Cruz OJ, Uckun FM. Microbicides for multidrug-resistant and multitropic HIV-1. Curr Opin Investig Drugs 2008;9:152-69. (Pubitemid 351206374)
11. Abdool Karim Q, Abdool Karim SS, Frohlich JA, CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-74.
12. Jespers VA, Van Roey JM, Beets GI, Buve AM. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immune Defic Syndr 2007;44:154-8 (Pubitemid 46292217)
13. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004;10:315-36 (Pubitemid 38072766)
14. Van Damme L, Chandeying V, Ramjee G, et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. AIDS 2000;14:85-8. (Pubitemid 30072081)
15. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008;3:e1474.
16. Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One 2008;3:e3784.
17. Roehr B. Microbicide offers no protection against HIV infection. BMJ 2009;339:b5538
18. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977-87.
19. Elinder M. Towards a new generation of anti-HIV drugs. Interaction kinetic analysis of enzyme inhibitors using SPR-biosensors. Digital comprehensive summaries of Uppsala dissertations from the Faculty of Science and Technology 834. Uppsala: Acta Universitatis Upsaliensis; 2011. Available from: http://urn.kb.se/resolve? urn=urn:nbn:se:uu:diva-152172 p. 66
20. D'Cruz OJ, Uckun FM. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Enzyme Inhib Med Chem 2006;21:329-50 (Pubitemid 44355782)
21. D'Cruz OJ, Uckun FM. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission. Curr HIV Res 2006;4:329-45. (Pubitemid 44027722)
22. Zussman A, Lara L, Lara HH, et al. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 2003;17:653-61 (Pubitemid 36521071)
23. Barnard J, Borkow G, Parniak MA. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 1997;36:7786-92 (Pubitemid 27287190)
24. Borkow G, Barnard J, Nguyen TM, et al. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 1997;71:3023-30 (Pubitemid 27119946)
25. Borkow G, Salomon H, Wainberg MA, Parniak MA. Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. AIDS Res Hum Retroviruses 2002;18:711-14 (Pubitemid 34765339)
26. Hossain MM, Parniak MA. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1. J Virol 2006;80:4440-6
27. D'Cruz OJ, Uckun FM. Discovery of 2,5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human immunodeficiency virus microbicide. Mol Hum Reprod 2005;11:767-77 (Pubitemid 43205505)
28. Kenney J, Aravantinou M, Singer R, et al. An antiretroviral/zinc combination gel provides 24 h of complete protection against vaginal SHIV infection in macaques. PLoS One 2011;6:e15835
29. Pani A, Musiu C, Loi AG, et al. DABOs as candidates to prevent mucosal HIV transmission. Antivir Chem Chemother 2001;12(Suppl 1):51-9
30. Cole AM. Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 2006;306:199-230 (Pubitemid 47400323)
31. Hickey DK, Patel MV, Fahey JV, Wira CR. Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol 2011;88:185-94
32. Fichorova RN, Bajpai M, Chandra N, et al. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 2004;71:761-9 (Pubitemid 39108635)
33. Weber J, Desai K, Darbyshire J; Microbicides Development Programme. The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med 2005;2(e142):392-5
34. Catalone BJ, Kish-Catalone TM, Neely EB, et al. Comparative safety evaluation of candidate vaginal microbicide C31G. Antimicrob Agents Chemother 2005;49:1509-20 (Pubitemid 40463383)
35. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor-alpha and interleukin-1 stimulate the human immunodeficiency virus enhancer by activation of nuclear factor kappa B. Proc Natl Acad Sci USA 1989;86:2336-40 (Pubitemid 19102503)
36. Febo IL, Beauchamp B. Prevention overview: role of microbicides in preventing HIV infection. HIV CareLink Newsletter July 13, 2011. Available from: www.FCAETC.org/Newsletter
37. Mayer KH, Karim SA, Kelly C, et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003;17:321-9 (Pubitemid 36223256)
38. Mauck CK, Weiner DH, Creinin MD, et al. A randomized phase I vaginal safety study of three concentrations of C31G vs. extra strength Gynol II. Contraception 2004;70:233-40 (Pubitemid 39119986)
39. Van der Straten A, Napierala S, Cheng H, et al. A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe. Contraception 2007;76:389-99 (Pubitemid 47600126)
40. Van de Wijgert JH, Braunstein SL, Morar NS, et al. Carraguard vaginal gel safety in HIV-positive women and men in South Africa. J Acquir Immune Defic Syndr 2007;46:538-46 (Pubitemid 350191046)
41. Eckstein P, Jackson MC, Millman N, Sobrero AJ. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J Reprod Fertil 1969;20:85-93
42. Belec L, Gherardi R, Payan C, et al. Proinflammatory cytokine expression in cervicovaginal secretions of normal and HIV-infected women. Cytokine 1995;7:568-74
43. Noguchi K, Tsukumi K, Urano T. Qualitative and quantitative differences in normal vaginal flora of conventionally reared mice, rats, hamsters, rabbits, and dogs. Comp Med 2003;53:404-12 (Pubitemid 37129300)
44. Stafford MK, Ward H, Flanagan A, et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:327-31
45. Centers for Disease Control and Prevention, August 4, 2000, posting date. Letter from the Director, National Center for HIV, STD, and TB Prevention. Available from: http://www.cdc.gov/hiv/pubs/mmwr/mmwr11aug00.htm
46. Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005;115:128-37 (Pubitemid 40385513)
47. Romano J, Variano B, Coplan P, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009;25:483-8
48. Mai A, Artico M, Sbardella G, et al. Dihydro(alkylthio)(naphthylmethyl) oxo pyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. J Med Chem 1997;40:1447-54 (Pubitemid 27200761)
49. Van Herrewege Y, Michiels J, Van Roey J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004;48:337-9 (Pubitemid 38040219)
50. Di Fabio S, Van Roey J, Giannini G, et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003;17:1597-604. (Pubitemid 36951680)
51. Nel AM, Smythe SC, Habibi S, et al. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 2010;55:161-9
52. Selhorst P, Vazquez AC, Terrazas-Aranda K, et al. Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrob Agents Chemother 2011;55:1403-13
53. Herrera C, Cranage M, McGowan I, et al. Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother 2009;53:1797-807
54. Kenney J, Aravantinou M, Singer R, et al. An antiretroviral/zinc combination gel provides 24 h of complete protection against vaginal SHIV infection in macaques. PLoS One 2011;6:e15835
55. Sudbeck EA, Mao C, Vig R, Uckun FM. Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1998;42:3225-33 (Pubitemid 28553745)
56. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant HIV. Antivir Chem Chemother 1999;10:233-40 (Pubitemid 29481703)
57. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Rational design of N-[2-(2,5-dimethoxyphenyl ethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (PHI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorg Med Chem Lett 1999;9:1593-8 (Pubitemid 29274203)
58. Uckun FM, Pendergrass S, Maher D, et al. N'-[2-(2-thiophene)ethyl[-N'-[2- (5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett 1999;9:3411-16.
59. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Structure-based drug design of nonnucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Biochem Pharmacol 2000;60:1251-65
60. Bell FW, Cantrell AS, Hogberg M, et al. Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. J Med Chem 1995;38:4929-36
61. Alcaro S, Alteri C, Artese A, et al. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine. ChemMedChem 2011;6:2203-13
62. Cantrell AS, Engelhardt P, Hogberg M, et al. Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2 Synthesis and further structure-activity relationship studies of PETT analogs. J Med Chem 1996;39:4261-74 (Pubitemid 26339837)
63. Sudbeck EA, Jennissen JD, Venkatachalam TK, Uckun FM. Inhibitor of HIV-1 reverse transcriptase: N'-(5-bromo-2-pyridyl)-N-[2-(2,5-dimethoxyphenyl)ethyl] thiourea. Acta Crystallogr C 1999;55:2122-4 (Pubitemid 129619346)
64. Ren J, Diprose J, Warren J, et al. Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses. J Biol Chem 2000;275:5633-9 (Pubitemid 30115202)
65. de Oliveira CF, Diaz RS, Machado DM, et al. Surveillance of HIV-1 genetic subtypes and diversity in the US blood supply. Transfusion 2000;40:1399-406
66. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005;192:958-66 (Pubitemid 41266791)
67. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-8 (Pubitemid 34755278)
68. Little SJ, Holte S, Routy J-P, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94 (Pubitemid 34851830)
69. Hanna GJ, Balaguera HU, Freedberg KA, et al. Drug-selected resistance mutations and non-B subtypes in antiviral-naive adults with established human immunodeficiency virus infection. J Infect Dis 2003;188:986-91 (Pubitemid 37268248)
70. McCutchan FE. Global epidemiology of HIV. J Med Virol 2006;78:S7-S12 (Pubitemid 43993457)
71. Uckun FM, Qazi S, Venkatachalam T. N'-[2-(2-thiophene) ethyl]-N'-[2-(5-bromopyridyl)]thiourea (HI-443), a rationally designed non-nucleoside reverse transcriptase inhibitor compound with potent anti-HIV activity. Arzneimittelforschung 2007;57:278-85. (Pubitemid 46883232)
72. Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev 2005;57:1692-712 (Pubitemid 41444256)
73. Acarturk F. Mucoadhesive vaginal drug delivery systems. Recent Pat Drug Deliv Formul 2009;3:193-205
74. Arzhavitna A, Steckel H. Foams for pharmaceutical and cosmetic application. Int J Pharm 2010;394:1-17
75. D'Cruz OJ, Samuel P, Uckun FM. Conceival, a novel non-contraceptive vaginal vehicle for lipophilic microbicides. AAPS PharmSciTech 2005;6:E56-64. (Pubitemid 41631000)
76. D'Cruz OJ, Samuel P, Uckun FM. PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide. Biol Reprod 2004;71:2037-47 (Pubitemid 39586952)
77. D'Cruz OJ, Uckun FM. Mucosal safety of PHI-443 and stampidine as a combination microbicide to prevent genital transmission of HIV-1. Fertil Steril 2007;88:1197-206 (Pubitemid 47520614)
78. Ayehunie S, Cannon C, Larosa K, et al. Development of an in vitro alternative assay method for vaginal irritation. Toxicology 2011;279:130-8
79. D'Cruz OJ, Erbeck D, Uckun FM. A study of the potential of the pig as a model for the vaginal irritancy of benzalkonium chloride in comparison to the nonirritant microbicide PHI-443 and the spermicide vanadocene dithiocarbamate. Toxicol Pathol 2005;33:465-76 (Pubitemid 40995486)
80. Squier CA, Mantz MJ, Schlievert PM, Davis CC. Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa. J Pharm Sci 2008;97:9-21
81. Uckun FM, Tibbles HE, Venkatachalam TK, Erbeck D. In vivo pharmacokinetics, metabolism, toxicity, and anti-HIV activity of N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]thiourea (HI-443), a potent non-nucleoside inhibitor of HIV reverse transcriptase. Arzneimittelforschung 2007;57:483-96. (Pubitemid 47234864)
82. DuMez D, Venkatachalam TK, Uckun FM. Large-scale synthesis of GMP grade N'-[2-(2-thiophene) ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (HI-443), a new anti-HIV drug candidate. Arzneimittelforschung 2007;57:330-8. (Pubitemid 47056001)
83. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3:112re4
84. Johnson TJ, Srinivasan P, Albright TH, et al. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 2011; Epub ahead of print
85. Watson Buckheit K, Yang L, Buckheit RW Jr. Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides. Antimicrob Agents Chemother 2011;55:5243-54